Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesAdjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer
European Journal of Surgical Oncology, 06/26/09
Knauer M et al. - In a study to investigate if extended chemotherapy (ExC) improved disease-free (DFS) and overall survival (OS) in early-stage breast cancer, it seems that ExC could not show advantages in terms of DFS and OS. Because multivariate analyses of retrospective data cannot account for all potential biases, these data require confirmation in randomized clinical trials. Until then, extended chemotherapy should be considered carefully. As in previous studies, no differences were found between neoadjuvant chemotherapy (NAC) and adjuvant therapy (AdC) groups.
Methods- 356 consecutive pts received NAC (45 pts), AdC (221 pts), or ExC (90 pts).
- These 3 groups were analyzed to determine effects of ExC and to identify pts who might benefit.
- NAC consisted in 93% of 3–6 cycles of epirubicin + docetaxel, AdC comprised EC ± taxanes in 72%.
- Median age in the NAC, AdC, and ExC-groups was 54, 56 and 52 yrs with follow-up of 30, 57, and 55 mos.
- After NAC, 35% achieved downstaging and 10% pathologic complete remission.
- ExC seemed to result in reduction of 5-yr DFS: vs 85% and 82% after NAC and AdC, DFS was 61% after ExC.
- OS was not significantly affected (79, 91, and 78% after NAC, AdC and ExC).
- In multivariate analysis after correction for age, menopausal status, stage, grading, hormone receptors, HER2-status, radiotherapy, and surgery, ExC seemed to adversely affect DFS, loco-regional and distant recurrence-rates.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09
Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy
Journal of the American College of Surgeons, 10/30/09
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Sponsor
Article Search
Sponsor